Analysis of short-chain fatty acid production through intestinal metabolomics and its relationship with body composition in patients with inflammatory bowel disease
Inflammatory bowel diseases; body fat percentage;
intestinal metabolomics, short-chain fatty acids; silymarin, beta-glucan.
Introduction: Inflammatory bowel diseases (IBD), including Crohn's Disease
(CD) and Ulcerative Colitis (UC) are a chronic inflammatory disorder and
idiopathic gastrointestinal tract (GIT). Among the causal factors of IBD, the following stand out:
Influence of the gut microbiota. Analyses of gut microbial communities
through high-throughput sequencing revealed significant differences in
composition between healthy individuals and those with CD, UC, and without IBD. The
metabolomics is one of the alternatives for the identification and differentiation of IBD, which
It can be defined as the comprehensive analysis of metabolites. Metabolic profiles
consist of molecules derived from the bacterial metabolism of the diet or
directly from the microbiota. Changes in many small molecules, such as acids
short-chain fats (SCFAs), microbial catabolites of tryptophan and bile acids,
have been identified in patients with IBD.